Nasdaq · CIK 0001395937
SNDX Syndax Pharmaceuticals Inc
Insider trading from SEC Form 4. Last filing Dec 1, 2025. Close $16.99 on Oct 9, 2026, +30% from the 52-week low and -32% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
8
with a Form 4 at this company
Price and insider trades, last year
SNDXOct 9, 2026 · close 16.99
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Syndax Pharmaceuticals Inc, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 25Weak | Michael A Metzger Chief Executive Officer sell | $2.6M 157,307 shares | -34% | +87% from low-25% from high | |
| 13Weak | Dennis Podlesak director sell | $875k 57,600 shares | -27% | +69% from low-32% from high | |
| 30Weak | Keith A. Goldan Chief Financial Officer sell | $12k 1,296 shares | -1% | +6% from low-58% from high | |
| 41Moderate | Michael A Metzger Chief Executive Officer sell | $70k 7,534 shares | -2% | +6% from low-58% from high | |
| 68Notable | Nicholas A.J. Botwood Head of R&D, CMO buy | $106k 11,765 shares | +50% | +1% from low-59% from high | |
| 57Moderate | Martin H. Huber Jr. director buy | $45k 5,000 shares | +7% | +4% from low-57% from high | |
| 60Notable | Keith Katkin director buy | $91k 10,000 shares | +11% | +4% from low-57% from high | |
| 36Weak | Neil Gallagher President, Head of R&D sell | $72k 4,618 shares | -5% | - | |
| 37Weak | Keith A. Goldan Chief Financial Officer sell | $59k 3,777 shares | -4% | - |
Transactions
The last 32 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 1, 2025 | Keith A. Goldan Chief Financial Officer | GGift Common Stock | -1,224 | $0.00 | $0 | 92,452 | Dec 1, 2025 |
| Sep 8, 2025 | Michael A Metzger Chief Executive Officer | MOption exercise Common Stock10b5-1 | +157,307 | $10.90 | $1.7M | 455,968 | Sep 8, 2025 |
| Sep 8, 2025 | Michael A Metzger Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -157,307 | $16.41 | $2.6M | 298,661 | Sep 8, 2025 |
| Sep 8, 2025 | Michael A Metzger Chief Executive Officer | MOption exercise Stock options (Right to buy)derivative10b5-1 | +157,307 | $0.00 | $0 | 0 | Sep 8, 2025 |
| Aug 14, 2025 | Dennis Podlesak director | MOption exercise Common Stock10b5-1 | +19,200 | $7.20 | $138k | 210,963 | Aug 18, 2025 |
| Aug 14, 2025 | Dennis Podlesak director | SOpen-market sale Common Stock10b5-1 | -19,200 | $14.19 | $273k | 191,763 | Aug 18, 2025 |
| Aug 15, 2025 | Dennis Podlesak director | MOption exercise Common Stock10b5-1 | +19,200 | $7.20 | $138k | 210,963 | Aug 18, 2025 |
| Aug 15, 2025 | Dennis Podlesak director | SOpen-market sale Common Stock10b5-1 | -19,200 | $15.54 | $298k | 191,763 | Aug 18, 2025 |
| Aug 18, 2025 | Dennis Podlesak director | MOption exercise Common Stock10b5-1 | +19,200 | $7.20 | $138k | 210,963 | Aug 18, 2025 |
| Aug 18, 2025 | Dennis Podlesak director | SOpen-market sale Common Stock10b5-1 | -19,200 | $15.84 | $304k | 191,763 | Aug 18, 2025 |
| Aug 14, 2025 | Dennis Podlesak director | MOption exercise Stock Options (Right to buy)derivative10b5-1 | -19,200 | $0.00 | $0 | 0 | Aug 18, 2025 |
| Aug 15, 2025 | Dennis Podlesak director | MOption exercise Stock Options (Right to buy)derivative10b5-1 | -14,400 | $0.00 | $0 | 0 | Aug 18, 2025 |
| Aug 15, 2025 | Dennis Podlesak director | MOption exercise Stock Options (Right to buy)derivative10b5-1 | -4,800 | $0.00 | $0 | 0 | Aug 18, 2025 |
| Aug 18, 2025 | Dennis Podlesak director | MOption exercise Stock Options (Right to buy)derivative10b5-1 | -19,200 | $0.00 | $0 | 0 | Aug 18, 2025 |
| Jul 31, 2025 | Keith A. Goldan Chief Financial Officer | JOther Common Stock | +1,226 | $8.43 | $10k | 93,676 | Aug 7, 2025 |
| Jul 16, 2025 | Michael A Metzger Chief Executive Officer | SOpen-market sale Common Stock | -7,534 | $9.29 | $70k | 298,661 | Jul 18, 2025 |
| Jul 16, 2025 | Keith A. Goldan Chief Financial Officer | SOpen-market sale Common Stock | -1,296 | $9.29 | $12k | 92,450 | Jul 18, 2025 |
| May 19, 2025 | Keith A. Goldan Chief Financial Officer | POpen-market purchase Common Stock | +3,000 | - | - | 93,746 | May 19, 2025 |
| May 19, 2025 | Martin H. Huber Jr. director | POpen-market purchase Common Stock | +5,000 | $8.99 | $45k | 79,000 | May 19, 2025 |
| May 19, 2025 | Keith Katkin director | POpen-market purchase Common Stock | +10,000 | $9.11 | $91k | 100,000 | May 19, 2025 |
| May 16, 2025 | Nicholas A.J. Botwood Head of R&D, CMO | POpen-market purchase Common Stock | +11,765 | $9.00 | $106k | 35,165 | May 19, 2025 |
| Feb 10, 2025 | Neil Gallagher President, Head of R&D | SOpen-market sale Common Stock | -4,618 | $15.50 | $72k | 85,095 | Feb 12, 2025 |
| Feb 10, 2025 | Keith A. Goldan Chief Financial Officer | SOpen-market sale Common Stock | -3,777 | $15.50 | $59k | 90,746 | Feb 12, 2025 |
| Feb 5, 2025 | Neil Gallagher President, Head of R&D | AGrant or award Common Stock | +18,500 | $0.00 | $0 | 66,313 | Feb 7, 2025 |
| Feb 5, 2025 | Keith A. Goldan Chief Financial Officer | AGrant or award Common Stock | +18,500 | $0.00 | $0 | 71,123 | Feb 7, 2025 |
| Feb 5, 2025 | Martin H. Huber Jr. director | AGrant or award Common Stock | +25,000 | $0.00 | $0 | 74,000 | Feb 7, 2025 |
| Feb 5, 2025 | Jennifer Jarrett director | AGrant or award Common Stock | +25,000 | $0.00 | $0 | 90,000 | Feb 7, 2025 |
| Feb 5, 2025 | Keith Katkin director | AGrant or award Common Stock | +25,000 | $0.00 | $0 | 90,000 | Feb 7, 2025 |
| Feb 5, 2025 | Neil Gallagher President, Head of R&D | AGrant or award Common Stock | +23,400 | $0.00 | $0 | 89,713 | Feb 7, 2025 |
| Feb 5, 2025 | Keith A. Goldan Chief Financial Officer | AGrant or award Common Stock | +23,400 | $0.00 | $0 | 94,523 | Feb 7, 2025 |
| Feb 5, 2025 | Neil Gallagher President, Head of R&D | AGrant or award Stock Options (Right to buy)derivative | +110,500 | $14.65 | $1.6M | 110,500 | Feb 7, 2025 |
| Feb 5, 2025 | Keith A. Goldan Chief Financial Officer | AGrant or award Stock Options (Right to buy)derivative | +110,500 | $14.65 | $1.6M | 110,500 | Feb 7, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Nicholas A.J. BotwoodHead of R&D, CMO
- Neil GallagherPresident, Head of R&D
- Keith A. GoldanChief Financial Officer
- Martin H. Huber Jr.ceo, president, officer, director
- Jennifer Jarrettcoo, officer, director, ceo, president
- Keith Katkindirector
- Michael A MetzgerChief Executive Officer
- Dennis Podlesakdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.